Deerfield Discovery and Development (3DC)
Deerfield’s internal research and development engine, 3DC, seeks to advance early-stage therapeutics from scientific discovery through preclinical proof of concept and into the clinic for the benefit of patients.
3DC is a company-building R&D engine.
Deerfield Discovery and Development (3DC) is a partner to various stakeholders in the biotech ecosystem, including principal investigators in Deerfield’s academic collaboration network, startups, and biopharma companies.
Researchers at academic institutions discover many of the novel insights that advance our understanding of disease. Commercially promising innovations eventually outgrow the lab, requiring greater resources and more focused development expertise than an academic setting can typically provide.
3DC is led by Chief Executive Officer Frank Nestle, MD.
Deeply experienced drug hunters seek to advance a competitive portfolio of high-impact medicines
Working with Entrepreneurs
3DC offers turnkey drug discovery expertise and capabilities to founders to advance the therapeutic development of small molecules and biologics.
Instead of building an R&D team from scratch, Deerfield-backed startups can leverage 3DC to advance development plans faster and in collaboration with seasoned biotech and pharma veterans on staff.
Partnering with Biopharma
Deerfield’s infrastructure can support the development of compelling assets on behalf of or in partnership with strategics and corporate partners.
Our team can acquire, transform, mature, and integrate development-stage and commercial assets prior to or in preparation for a corporate acquisition.
.jpg)
Laboratory Space at Cure
3DC scientists enjoy access to in-building laboratory facilities including state-of-the-art equipment like cryo-EM, NMR, flow cytometry, automated screening robots, and high-throughput mass spectrometry.
Deerfield partners with leading academic research centers, aiming to provide critical funding and expertise to sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.
In November 2020, Deerfield and Boston Children’s Hospital, which has the largest National Institutes of Health-funded pediatric research enterprise in the United States, announced a major research collaboration, Blackfan Circle Innovations. Blackfan Circle Innovations intends to advance promising therapeutics that will address unsolved medical needs and find cures for disease.
In April 2018, Deerfield and Vanderbilt University announced the launch of Ancora Innovation, LLC, a Deerfield company that will support Vanderbilt’s innovative life science research and leverage Deerfield’s expertise in accelerating state-of-the-art drug development.
In January 2022, Deerfield and Stanford University announced the creation of Porter Alliance for Innovative Medicines, a collaboration to accelerate translational research into clinical therapeutics.
In April 2019, Deerfield and the University of Illinois at Chicago announced the establishment of West Loop Innovations. The company will help accelerate the commercialization of therapeutics developed at UIC.